From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 13.12 forward earnings, which is lower than 14.74 for the industry.

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen's Lumakras & Bristol Myers' Krazati ...

Amgen is a leader in biotechnology-based human ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, ...

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, its strong top-line performance caught investor attention. Amgen’s total ...

Amgen is a leader in biotechnology-based human ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon ...

Amgen Inc. (NASDAQ:AMGN ... Our innovative oncology portfolio, including BLINCYTO, IMDELLTRA, LUMAKRAS, Vectibix, KYPROLIS, Nplate and XGEVA grew 10% year-over-year generating over $2 billion ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...